1709-53-1

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-N-ETHYL-BENZENESULFONAMIDE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of antibacterial and diuretic agents. Its presence in the molecular structure of these drugs aids in their therapeutic effects.
Used in Dye Industry:
In the dye industry, 4-AMINO-N-ETHYL-BENZENESULFONAMIDE is used as an intermediate in the production of dyes, where its chemical properties contribute to the color and stability of the final products.
Used in Organic Chemistry:
4-AMINO-N-ETHYL-BENZENESULFONAMIDE is used as a versatile building block in organic chemistry for its primary amine and sulfonamide functional groups, which facilitate a wide range of chemical reactions and the creation of diverse chemical compounds.

InChI:InChI=1/C8H12N2O2S/c1-2-10-13(11,12)8-5-3-7(9)4-6-8/h3-6,10H,2,9H2,1H3

Upstream product

• 28860-08-4 4-nitrobenzenesulfonyl ethylamine 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 
• 349128-19-4 N-[4-(ethylaminosulfonyl)phenyl]acetamide 

Downstream Products

• 503183-17-3 4-[N'-(3,5-diaminopyrazol-4-ylidene)hydrazino]-N-ethylbenzenesulfonamide 
• 1028253-48-6 N-(4-(ethylsulfamoyl)phenyl)-3-methyl-D-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 1028253-47-5 N-(4-(ethylsulfamoyl)phenyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 726144-38-3 C₉H₁₀N₂O₂S₂ 
• 1383478-97-4 C₂₇H₃₁N₃O₃S₂ 
• 1028253-49-7 2-(4-(N-ethylsulfamoyl)phenylamino)-3,3-dimethylbutanoic acid 

Relevant academic research and scientific papers

Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study

Focal adhesion kinase (FAK) is an intracellular non-receptor tyrosine kinase responsible for development of various tumor types. Aiming to explore new potent inhibitors, two series of 2,4-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives were designed and synthesized on the base of structure-based design strategy. Biological evaluation indicated that most of these new compounds could potently inhibit FAK kinase, leading to the promising inhibitors against the proliferation of U-87MG, A-549, and MDA-MB-231 cancer cell lines. Among them, the optimized compound 18h potently inhibited the enzyme (IC50 = 19.1 nM) and displayed stronger potency than TAE-226 in U-87MG, A-549 and MDA-MB-231 cells, with IC50 values of 0.35, 0.24, and 0.34 μM, respectively. Compound 18h is a multi-target kinase inhibitor. Furthermore, compound 18h also exhibited relatively less cytotoxicity (IC50 = 3.72 μM) toward a normal human cell line, HK2. According to the flow cytometry and wound healing assay results, compound 18h effectively induced apoptosis and G0/G1 phase arrest of MDA-MB-231 cells and suppressed the migration of U-87MG, A-549 and MDA-MB-231 cells. The docking study of compound 18h was performed to elucidate its possible binding modes and to provide a structural basis for the further structural guidance design of FAK inhibitors. Collectively, these data support the further development of compound 18h as a lead compound for FAK-targeted anticancer drug discovery.

Novel Allosteric Activators for Ferroptosis Regulator Glutathione Peroxidase 4

Glutathione peroxidase 4 (GPX4) is essential for cell membrane repair, inflammation suppression, and ferroptosis inhibition. GPX4 upregulation provides unique drug discovery opportunities for inflammation and ferroptosis-related diseases. However, rationa

Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors

Screening of the NCI Diversity Set-1 identified PI-083 (NSC-45382) a proteasome inhibitor selective for cancer over normal cells. Focused libraries of novel compounds based on PI-083 chloronaphthoquinone and sulfonamide moieties were synthesized to gain a better understanding of the structure-activity relationship responsible for chymotrypsin-like proteasome inhibitory activity. This led to the demonstration that the chloronaphthoquinone and the sulfonamide moieties are critical for inhibitory activity. The pyridyl group in PI-083 can be replaced with other heterocyclic groups without significant loss of activity. Molecular modeling studies were also performed to explore the detailed interactions of PI-083 and its derivatives with the β5 and β6 subunits of the 20S proteasome. The refined model showed an H-bond interaction between the Asp-114 and the sulfonamide moiety of the PI-083 in the β6 subunit.

NOVEL ADENOSINE A3 RECEPTOR AGONISTS

The invention realizes that a series of sulfonamido derivatives with a conserved uronamide group at the 5' position provide superior A3 receptor affinity as well as selectivity. These new adenosine agonists are sulfonamido deritatives N-substituted with aliphatic groups (cyclic or linear) or aromatic radicals.